Geron Corporation (GERN) stock price, news, quote and history
This page provides comprehensive financial information for Geron Corporation (GERN), a commercial-stage biopharmaceutical company. It includes the current stock price, historical data, key financial metrics, an overview of their oncology product pipeline, and analyst insights. The company's stock showed a slight increase in pre-market trading, and its product pipeline features several clinical-stage therapeutics for various cancers.
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
Geron Corporation announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, where members of its management team will hold a fireside chat. The company, a commercial-stage biopharmaceutical firm, is focused on treating blood cancer and has its telomerase inhibitor RYTELO® (imetelstat) approved for specific myelodysplastic syndromes. Geron is also advancing imetelstat through clinical trials for other hematologic malignancies.
Geron executives to speak April 13 at Needham healthcare webcast
Geron (Nasdaq: GERN) announced that its management team will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 11:00 a.m. ET. A live and archived audio webcast will be available through the Investors & Media section of Geron’s website. This event is part of Geron's ongoing investor outreach following the commercial launch of RYTELO and recent financial updates.
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
Geron Corporation announced its management team will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 11:00 a.m. ET. The biopharmaceutical company focuses on changing lives by altering the course of blood cancer.
Geron Corporation’s Strategic Moves Amplify Stocks in Q1 2026
Geron Corporation's stock surged by 9.73% following promising clinical trial results for its flagship drug RYTELO and strategic corporate maneuvers. The company reported strong 2025 financial results, outlined future capital opportunities through securities registration, and strengthened its executive board with new biopharma leadership, signaling an aggressive push for commercial expansion in hematologic research.
Geron (NASDAQ:GERN) Share Price Passes Above 200 Day Moving Average - What's Next?
Geron (NASDAQ:GERN) stock recently crossed above its 200-day moving average, a key technical indicator. Despite this technical performance, the company missed its recent quarterly EPS and revenue estimates and faces mixed analyst ratings, with a consensus "Hold" but varying Buy, Hold, and Sell recommendations. Institutional investors maintain significant ownership, with RA Capital and Vanguard leading the holdings.
Geron Corp Stock: Biotech Investor Focus on RYTELO Commercialization and Valuation Gap Amid Market V
Geron Corp is transitioning from a development-stage biotech to a revenue-generating entity with its flagship product RYTELO, approved for myelodysplastic syndromes. The company faces market volatility but is poised for growth due to RYTELO's unique mechanism and addressable market. Investors are closely watching commercialization efforts, pipeline expansion into myelofibrosis, and the potential for the stock to close its valuation gap.
Geron (GERN) director Patricia Andrews submits initial insider ownership filing
Geron Corp director Patricia S. Andrews has filed an initial insider ownership report (Form 3) with the SEC, establishing her status as a director. The filing outlines her beneficial ownership of securities, showing no transactions in this initial report, meaning no shares were bought or sold. This Form 3 primarily serves to disclose her baseline holdings without indicating any changes in ownership.
Geron Adds Biopharma Veterans As RYTELO Commercialization And Valuation Scrutinized
Geron Corporation has appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors, bringing commercial operations and business development expertise. These appointments are crucial as Geron focuses on the commercialization of its key product, RYTELO, and aims to strengthen its market position. The company's stock is currently trading significantly below analyst targets and estimated fair value, with recent weak short-term sentiment.
Geron (GERN) director Constantine Chinoporos files initial Form 3
Geron Corp director Constantine Chinoporos has filed an initial ownership statement (Form 3) with the SEC, establishing his status as a company insider. This filing indicates he is a director but does not report any stock transactions or derivative positions at this time. The Form 3 confirms no securities are beneficially owned by him to date.
Vanguard (NASDAQ: GERN) discloses 0 share ownership after realignment
The Vanguard Group has filed an Amendment No. 1 to a Schedule 13G/A, reporting 0 beneficial ownership of Geron Corp (GERN) common stock, representing 0% of the class. This change is due to an internal realignment effective January 12, 2026, which disaggregates reporting for certain Vanguard subsidiaries and divisions. The filing clarifies that this is an administrative reclassification of reporting responsibility rather than an explicit market transaction, and it was signed by Ashley Grim, Head of Global Fund Administration.
Geron (NASDAQ: GERN) director granted 270,000 stock options at $1.57 strike
Geron Corp director Constantine Chinoporos was granted 270,000 stock options with an exercise price of $1.57 per share, expiring on March 24, 2036. These options will vest in three equal annual installments starting March 25, 2027, contingent on his continued service. This was an option award, not an open-market share purchase, and he now holds 270,000 stock options directly.
Geron Corporation Form 8-K Filing Details for March 25, 2026: Company Information, Stock Symbol, and SEC Compliance 16
Geron Corporation announced the election of two new independent directors, Patricia S. Andrews and Constantine Chinoporos, to its Board of Directors on March 25, 2026. Patricia S. Andrews has also been appointed to the Audit Committee, which is expected to enhance financial oversight. The company, which trades under the symbol GERN on NASDAQ, has entered into standard indemnification agreements with the new directors to provide legal protection.
Geron (GERN) grants director 270,000 stock options at $1.57
Geron Corporation announced that director Patricia S. Andrews was granted 270,000 stock options with an exercise price of $1.57 per share. These options, which expire on March 24, 2036, will vest in three equal annual installments beginning March 25, 2027, provided her continuous service with the company. This grant increases her direct holdings to 270,000 stock options.
[8-K] GERON CORP Reports Material Event
Geron Corporation announced the election of Patricia S. Andrews and Constantine Chinoporos as Class III directors to its Board, effective immediately. Their terms will run until the 2026 Annual Meeting of Stockholders. Both new directors will receive standard cash and equity compensation and will enter into the company's standard indemnification agreements.
Geron brings in 2 biopharma veterans as RYTELO push builds
Geron (Nasdaq: GERN) has appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors, bringing extensive biopharmaceutical leadership and commercial-stage experience. Both veterans will support Geron's commercial strategy to enhance growth for its RYTELO treatment, an approved therapy for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS). Their expertise is expected to be instrumental in driving patient access, sales, and long-term commercial success for RYTELO.
Geron Corp stock advances on imetelstat FDA approval momentum and pipeline updates
Geron Corp's stock is gaining investor interest due to the recent FDA approval of its lead drug, imetelstat (branded Rytelo), for low-risk myelodysplastic syndromes (LR-MDS). The company plans a Q1 2025 launch and projects significant market share and revenue from the drug. Beyond imetelstat, Geron is also advancing other pipeline candidates and aims for profitability by 2027, making it an attractive prospect for biotech investors.
GERN SEC Filings - Geron Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Geron (GERN) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-powered summaries of key developments. It details the company's focus on blood cancers, recent material events such as executive changes and financial guidance for RYTELO, and offers insights into insider trading and corporate actions. The platform aims to help investors efficiently track Geron's regulatory history, financial performance, and clinical progress.
Geron’s Strategic Push: RYTELO’s Rising Global Ambitions
Geron Corporation saw an 8.56% surge in its stock, driven by FDA approval for RYTELO and promising clinical trial results, specifically for second-line lower-risk MDS. The company anticipates RYTELO revenues between $220 million and $240 million in 2026, alongside disciplined spending. Despite a Q4 revenue shortfall, management remains optimistic, focusing on RYTELO's commercialization and upcoming data catalysts.
Geron's cancer screening patent rejected as non-patentable under Indian law
US-based biotechnology company Geron Corp. had its cancer screening patent application rejected by the Delhi High Court. The ruling highlighted India's strict patent laws and disregarded the fact that Geron had secured similar patents in the US, Europe, and Japan. This decision underscores India's stringent approach to patentability, especially when considering medical-related inventions.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation granted stock options to six new employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants totaled 956,250 shares with an exercise price matching the closing price on the grant date, vesting over four years. Geron is a commercial-stage biopharmaceutical company focused on blood cancer treatments.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation has reported granting inducement stock options to six new employees, totaling 956,250 shares of common stock. These options, with an exercise price of $1.62 per share, vest over four years and were issued in accordance with Nasdaq Listing Rule 5635(c)(4) to attract talent. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with an approved drug, RYTELO®, for certain myelodysplastic syndromes.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it granted inducement stock options to six new employees to purchase 956,250 shares of common stock. These options, with an exercise price of $1.62 per share, vest over four years and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of the company's 2018 Inducement Award Plan, reinforcing Geron's commitment as a commercial-stage biopharmaceutical firm focusing on blood cancer treatments.
Geron Details RYTELO Growth Plan, $220M-$240M 2026 Sales Guide and MF Trial Catalyst at Barclays Conference
Geron Corporation presented its commercial strategy for RYTELO, aiming for $220M–$240M in 2026 sales, an increase from $184M in 2025, while reducing operating expenses. The company also highlighted significant commercial traction with 9% demand growth in Q4 2025 and 1,300 purchasing accounts. A key future catalyst is the Phase 3 IMPACT MF trial, which is fully enrolled with an interim analysis expected in the second half of 2026, focusing on overall survival as the primary endpoint.
Geron (NASDAQ:GERN) Shares Up 8.5% - Should You Buy?
Geron Corporation (NASDAQ: GERN) saw its shares climb 8.5% on Monday, trading with significantly lower volume than average. The company faces mixed analyst sentiment, holding a consensus "Hold" rating despite missing Q4 earnings and revenue estimates. Investor interest is driven by its lead drug, imetelstat, currently in Phase II/III trials, and substantial institutional ownership.
Geron (NASDAQ:GERN) Stock Price Passes Above Two Hundred Day Moving Average - Here's What Happened
Shares of Geron (NASDAQ:GERN) have risen above their 200-day moving average, trading at $1.58 after hitting a high of $1.63, with significant trading volume. The company previously missed quarterly earnings estimates, reporting an EPS of ($0.05) against an expected ($0.03) and revenue of $48.02M versus $50.43M. Analyst ratings are mixed with a consensus "Hold" and an average target price of $2.17.
Geron Corporation (GERN) Reports Q4 EPS of (5c)
Geron Corporation (GERN) reported Q4 EPS of (5c), missing consensus estimates of (4c), with revenue of $48M, also below estimates. Despite themiss, CEO Harout Semerjian highlighted strategic actions to drive RYTELO demand and lower operating expenses, along with anticipated catalysts in the second half of 2026. The company forecasts Rytelo net product revenue of $220M to $240M for fiscal year 2026 and expects existing cash and sales to fund future operating requirements.
11 Fastest Growing Penny Stocks to Buy Right Now
This article identifies 11 fastest-growing penny stocks, focusing on Geron Corporation (NASDAQ: GERN) as an example. It details Geron's Q4 earnings, RYTELO's commercial strategy, and future catalysts, along with financial expectations for FY 2026. The company is a biopharmaceutical firm specializing in oncology.
Geron Corporation $GERN Shares Sold by Segall Bryant & Hamill LLC
Segall Bryant & Hamill LLC significantly reduced its stake in Geron Corporation (NASDAQ:GERN) by 25.8% in Q3, selling 1,856,968 shares, though institutional ownership remains high at 73.71%. Other institutional investors like Squarepoint Ops LLC and Candriam S.C.A. increased their positions, indicating active trading interest. Geron is currently trading around $1.47 with a $941.59 million market cap, missed its Q3 earnings estimates, and has a consensus analyst "Hold" rating with a target price of $2.17.
Soleus files 5.2% stake in Geron (GERN) via master fund
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 5.2% beneficial ownership stake in Geron Corporation (GERN), comprising 33,008,659 shares. This disclosure was made through a Schedule 13G SEC filing, indicating a passive investment. The reported percentage is based on Geron's outstanding share count as of February 20, 2026.
Geron (GERN) 2025 Revenue Surges to $183.6M Driven by RYTELO Commercial Success
Geron Corporation reported strong financial results for 2025, with RYTELO generating $183.6 million in full-year net product revenue, driven by increased demand and expanded ordering accounts. The company also implemented a workforce reduction to optimize operating expenses and reiterated its 2026 revenue guidance for RYTELO between $220 million and $240 million, while continuing research and exploring international markets.
Geron 10-K: Revenue $183.9M, EPS (0.13)
Geron reported total revenues of $183.9 million for the year, primarily from RYTELO sales, and a basic and diluted net loss per share of $(0.13), showing improvement from the prior year. The company's net loss narrowed to $(83.5) million from $(174.6) million in 2024, reflecting a successful transition to product commercialization. These financial results highlight the impact of RYTELO's launch in the U.S. and EU marketing authorization, alongside strategic operational scaling and cost reduction efforts.
Geron Corp. 2025 Financial Results: Q4 Loss of $31.1M, Annual Revenue $183.9M - News and Statistics
Geron Corp. reported a net loss of $31.1 million for the fourth quarter of 2025, or five cents per share, aligning with analyst forecasts for adjusted earnings. The biotechnology firm recorded $48 million in revenue for the quarter. For the full fiscal year 2025, Geron disclosed an annual net loss of $85.8 million, or 13 cents per share, with total annual revenue reaching $183.9 million.
GERN Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive overview of Geron Corp's (GERN) financial statements, including its income statement, balance sheet, and cash flow for both annual and quarterly periods. It highlights key financial metrics like EBITDA, free cash flow, net income, and EPS, and analyzes the company's financial health through metrics such as Piotroski F-Score, earnings quality, and interest coverage. The analysis indicates that Geron Corp has weak financial health, with negative net income and concerns regarding its ability to service debt.
Geron (GERN) Pops on FDA Nod: Is This Small-Cap Biotech Now Underpriced?
Geron (GERN) has seen significant investor attention and a surge in stock activity following FDA approval for its blood cancer drug, imetelstat. The approval turns Geron into a commercial-stage biotech, moving it from a pre-revenue company to one with potential cash flows. While analysts are generally constructive, with some bullish price targets, there are also concerns regarding execution risk, single-product concentration, and potential future equity dilution.
Geron Corporation (NASDAQ:GERN) Q4 2025 Earnings Call Transcript
Geron Corporation held its Q4 2025 earnings call, reporting Rytelo net revenue of $48 million for the quarter and $184 million for the full year 2025. The company shared its strategic focus on second-line lower-risk MDS patients for Rytelo, aiming for 2026 net revenue of $220 million to $240 million. Management also discussed commercial strategies, medical engagement, and financial discipline, including a reduction in operating expenses for 2026.
RYTELO drives Geron (GERN) 2025 revenue surge and 2026 guidance
Geron Corporation reported significant revenue growth in 2025, primarily driven by its blood cancer drug RYTELO, with net product revenue reaching $183.6 million. The company's net loss narrowed to $85.8 million, an improvement from the previous year, partly due to lower R&D expenses but with increased selling, general, and administrative costs for commercial expansion. Geron also provided strong 2026 guidance for RYTELO net product revenue and outlined its financial stability, reinforced by a cash position of over $401 million.
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts
Geron Corporation (NASDAQ:GERN) has received a consensus "Hold" rating from ten brokerages, with an average 1-year price target of $2.75. The stock's performance is significantly influenced by its lead drug, imetelstat, which recently received a positive FDA advisory panel vote for hematologic cancers. Institutional investors and hedge funds hold a substantial 73.71% of the company's stock.
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Geron Corporation announced its financial results for the fourth quarter and full year 2025, reporting RYTELO net product revenue of $48 million and $184 million, respectively. The company also provided 2026 financial guidance, projecting RYTELO net product revenue between $220 million and $240 million, and total operating expenses between $230 million and $240 million. Geron emphasized its strategic focus on driving RYTELO demand growth, expanding its reach outside the U.S., and maintaining financial discipline as it transforms into a leading hematology company.
Geron stock falls as Q4 results miss forecasts (GERN:NASDAQ)
Geron Corporation's stock dropped approximately 15% in premarket trading after the company's Q4 2025 results missed Street forecasts. The cancer drug developer, which makes Rytelo, reported a net loss of $0.05 per share, and reaffirmed its full-year outlook despite the Q4 miss.
Why Did GERN Stock Tumble 10% Pre-Market Today?
Geron (GERN) stock fell over 10% pre-market after reporting fourth-quarter and full-year 2025 results that missed analyst estimates for both revenue and loss per share. Despite missing estimates, the company highlighted rising sales of its blood cancer therapy RYTELO and projected RYTELO revenue between $220 million and $240 million for 2026. Geron also initiated a workforce reduction in December, affecting about one-third of its employees.
Geron (GERN) Q4 2025 Earnings Call Transcript
Geron Corporation reported full-year 2025 Rytelo net revenue of $184 million and issued 2026 revenue guidance of $220 million to $240 million, driven by targeted commercial efforts for second-line lower-risk MDS patients. The company outlined a strategy focused on increasing Rytelo awareness and expanding research partnerships, while also demonstrating financial discipline through reduced operating expenses for 2026. Management also provided updates on the IMPACT MF trial and European expansion plans for Rytelo.
Geron: Overview of Fourth Quarter Financial Results
Geron Corp. reported a net loss of $31.1 million, or 5 cents per share, for the fourth quarter, which narrowed to 3 cents per share after accounting for restructuring expenses. This loss was in line with Wall Street expectations. However, the company's Q4 revenue of $48 million fell short of analysts' projections of $50.7 million. For the full year, Geron recorded a total loss of $85.8 million on revenues of $183.9 million.
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Geron Corporation announced its financial results for Q4 and full year 2025, reporting $48 million in net product revenue for the quarter and $184 million for the full year, a significant increase from 2024. The company also highlighted operational achievements including increased RYTELO demand and new medical publications supporting its potential in LR-MDS. Geron reiterated its 2026 financial guidance and outlined future strategies for commercial growth and clinical trial advancements for RYTELO.
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Geron Corporation announced its financial results for Q4 and full year 2025, reporting RYTELO net product revenue of $48 million and $184 million, respectively, and reiterating 2026 revenue guidance of $220-240 million. The company ended 2025 with strong cash reserves of $401 million and outlined strategic priorities including driving U.S. commercial growth for RYTELO, exploring international expansion, and maintaining financial discipline. Geron also highlighted recent business achievements such as increased RYTELO demand, growth in ordering accounts, and new medical publications supporting the drug's efficacy.
Geron Corporation Q4 Financial Announcement Sparks Investor Curiosity
Geron Corporation's stock has risen by 9.32% due to positive FDA designations and clinical trial results, despite analysts adjusting its price target down from $4 to $3 while maintaining a "Buy" rating. The company is set to release its Q4 and full-year 2025 financial results on February 25, 2026, as it continues developing blood cancer treatments. Investors are keenly watching the upcoming announcement for insights into the company's financial health and the progress of its ongoing trials.
Geron earnings up next: Can RYTELO sustain revenue momentum?
Geron Corporation is set to report its Q4 and full-year 2025 earnings, with investors closely watching the performance of its lead blood cancer drug, RYTELO. Analysts anticipate a sequential improvement in revenue to $50.76 million, but EPS estimates have declined, indicating some uncertainty about near-term profitability. The company's ability to sustain RYTELO's commercial momentum and provide commentary on its 2026 revenue guidance of $220-$240 million will be key for investors.
Assessing Geron (GERN) Valuation After 2026 RYTELO Revenue Outlook And Pipeline Progress
Geron (GERN) has released its 2026 financial guidance, projecting RYTELO net product revenue of US$220 million to US$240 million and a reduction in operating expenses. The stock has seen a significant short-term price increase, but its long-term performance has been more challenging. Analysts currently estimate Geron's fair value at $3.33, suggesting it is undervalued, contingent on RYTELO's continued success and positive myelofibrosis trial data.
Biotech Geron lines up March investor talks in Boston and Miami
Geron (Nasdaq: GERN) announced that its management team will present at three investor conferences in March 2026: the TD Cowen 46th Annual Healthcare Conference in Boston, the Barclays 28th Annual Global Healthcare Conference in Miami, and the Leerink Partners Global Healthcare Conference for in-person meetings in Miami. The company expects to provide live and archived audio webcasts of the fireside chats on its website. This news, published on February 23, 2026, was followed by a 5.85% decline in GERN's stock price, indicating a negative market reaction.
Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT
Geron Corporation (NASDAQ:GERN) has announced its financial guidance for 2026, projecting RYTELO net product revenue between $220 million and $240 million and total operating expenses of $230 million to $240 million. This outlook anticipates revenue growth and reduced operating expenses year-over-year. Concurrently, TD Cowen analyst Tara Bancroft lowered the price target on GERN from $4 to $3, while maintaining a Buy rating, ahead of the company's Q4 results.
